|
|
|
|
|
|
|
19.01.26 - 18:03
|
Valneva Provides Update on Chikungunya Vaccine IXCHIQ® (GlobeNewswire EN)
|
|
|
Saint Herblain (France), January 19, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Company has decided to voluntarily withdraw the biologics license application (BLA) and Investigational New Drug (IND) application for its chikungunya vaccine, IXCHIQ®, in the United States, following suspension of the license by the U.S. Food and Drug Administration (FDA) in August 2025. The Company had been awaiting further information with respect to its formal response to the vaccine license suspension. Valneva was recently informed of the FDA's further decision to now place the Investigational New Drug (IND) on clinical hold pending an investigation of a newly reported foreign Serious Adverse Event (SAE)....
|
|
|
09.01.26 - 07:03
|
Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference (GlobeNewswire EN)
|
|
|
Saint Herblain (France), January 09, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that members of its management team will meet one-on-one with existing shareholders and hold meetings with other institutional specialist investors during the 44th Annual J.P. Morgan Healthcare Conference, January 12-14, 2026, in San Francisco....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.12.25 - 17:48
|
Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ® (GlobeNewswire EN)
|
|
|
Saint-Herblain (France), December 10, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive final antibody persistence and safety data for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its single-shot chikungunya vaccine, IXCHIQ®, in 304 children, twelve months after vaccination. Partially funded by the Coalition for Epidemic Preparedness Innovations (CEPI), with support from the European Union, the trial results continue to support future Phase 3 development in children, which the Company plans to initiate after gathering additional real-world experience in the adolescent population....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26.11.25 - 17:33
|
Valneva to Further Consolidate its Operations in France (GlobeNewswire EN)
|
|
|
Saint-Herblain (France), November 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced a strategic initiative to optimize its organizational footprint in France as part of the Company's ongoing efforts to increase operational effectiveness and position Valneva for long-term success. ...
|
|
|
26.11.25 - 12:48
|
Valneva: Starke Daten zu Hoffnungsträger – Aktie zieht kräftig an (Der Aktionaer)
|
|
|
Positive Studiennews beflügeln zur Wochenmitte die Aktie des Impfstoffherstellers Valneva. Das Unternehmen hat heute neue positive Ergebnisse aus der Phase-2-Studie zum Impfstoffkandidaten VLA15 gegen Lyme-Borreliose gemeldet. Die Daten zeigen sechs Monate nach der dritten Auffrischung eine starke Immunreaktion in allen Altersgruppen und ein weiterhin gutes Sicherheitsprofil....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
